Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, March 10, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its...
Thai Scientists from Chula to Investigate Global Warming in Antarctica
BANGKOK, March 10, 2025 /PRNewswire/ -- Prof. Dr. Suchana Chavanich from the Department of Marine Science , Faculty of Science, and Deputy Director of the Aquatic Resources Research Institute, Chulalongkorn University recently embarked on a 28-day...
HASHKEY GLOBAL PARTNERS WITH VERIFYVASP TO EXPAND GLOBAL TRAVEL RULE COMPLIANCE
Strategic partnership strengthens regulatory compliance across HashKey Global's international exchange network. SINGAPORE, March 10, 2025 /PRNewswire/ -- HashKey Global, a leading licensed exchange, and VerifyVASP, a global Travel Rule solution...
Webull Singapore launches trading competition for Singapore traders
SINGAPORE, March 10, 2025 /PRNewswire/ -- Webull Securities (Singapore) Pte Ltd ("Webull Singapore"), a subsidiary of Webull Corporation, a leading digital investment platform, has officially launched a trading competition designed to challenge...
RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., March 10, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was...
China Telecom and Partners Innovate Together! 5G UAV Medical Delivery Network Wins Global Mobile Award
HONG KONG, March 10, 2025 /PRNewswire/ -- On March 5, during the 2025 Mobile World Congress (MWC25), the 5G UAV medical delivery network solution jointly developed by China Telecom, Hangzhou Antwork Network Technology and Zhejiang University was...
AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the...
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
O MLYCLO ® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference...